ContraFect (CFRX) Short Interest Ratio & Short Volume

Short interest is the volume of ContraFect shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 59,600 shares of CFRX short. 1.09% of ContraFect's shares are currently sold short. Learn More on ContraFect's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.09% of ContraFect's floating shares are currently sold short.

ContraFect saw a drop in short interest in the month of October. As of October 31st, there was short interest totaling 59,600 shares, a drop of 48.6% from the previous total of 116,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

ContraFect currently has issued a total of 10,700,000 shares. Some of ContraFect's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. ContraFect currently has a public float of 5,480,000 shares.

1.09% of ContraFect's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to ContraFect: PainReform Ltd. (17.37%), Shuttle Pharmaceuticals Holdings, Inc. (21.28%), Entero Therapeutics, Inc. (9.51%), ZyVersa Therapeutics, Inc. (14.10%), Oncternal Therapeutics, Inc. (0.54%), Salarius Pharmaceuticals, Inc. (5.43%), Bio-Path Holdings, Inc. (8.03%), Processa Pharmaceuticals, Inc. (43.41%), GRI Bio, Inc. (34.61%), China SXT Pharmaceuticals, Inc. (0.37%),

As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($9.07 billion), T-Mobile US, Inc. ($3.71 billion), Charter Communications, Inc. ($3.51 billion), Occidental Petroleum Co. ($2.81 billion), Lululemon Athletica Inc. ($2.35 billion), Tractor Supply ($2.26 billion), Coinbase Global, Inc. ($1.88 billion), Rivian Automotive, Inc. ($1.71 billion), Celsius Holdings, Inc. ($1.67 billion), and Newmont Co. ($1.66 billion). View all of the most shorted stocks.

Short selling CFRX is an investing strategy that aims to generate trading profit from ContraFect as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for ContraFect occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CFRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CFRX, twice per month. The most recent reporting period available is October, 31 2023.